Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 5 Model-simulated versus clinically- measured TTP

From: Predicting response to pembrolizumab in metastatic melanoma by a new personalization algorithm

Simul. TTP Clinic. TTP
0–90 days 90–150 days 150–365 days No progressive disease during follow-up
0–90 days 8 (14.8%) 0 (0%) 2 (3.7%) 0 (0%)
90–150 days 0 (0%) 3 (5.6%) 0 (0%) 0 (0%)
150–365 days 0 (0%) 0 (0%) 2 (3.7%) 0 (0%)
No progressive disease during follow-up 2 (3.7%) 1 (1.85%) 1 (1.85%) 35 (64.8%)
  1. The simulated TTP (Simul.) was obtained by fitting the simulations of the mathematical model in Eq. (1) to the clinical results (Clinic.). The cells in the table include the number of cases and the percentage of the total number of patients in the cohort, (in brackets; N = 54), which satisfy one of the six possible outcomes described in the “Methods” section. The italicized numbers represent the number of cases, for which the algorithm correctly predicted whether progression will occur, and correctly predicted the time interval during which progression would occur; Cohen’s κ = 0.773